Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-252-7 | CAS number: 136-60-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 2011-07-20 to 2012-03-26
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- OECD 422, Section 4: Health Effects, 1996
- Deviations:
- yes
- Remarks:
- No chemical analysis of the test solutions prepared was carried out
- Qualifier:
- according to guideline
- Guideline:
- other: OPPTS 870.3650.2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- The study followed the SOP-M 285 and accomplished in agreement with the OECD 422, 1996, Section 4, and OPPTS 870.3650.2000.
- Limit test:
- no
Test material
- Reference substance name:
- Butyl benzoate
- EC Number:
- 205-252-7
- EC Name:
- Butyl benzoate
- Cas Number:
- 136-60-7
- Molecular formula:
- C11H14O2
- IUPAC Name:
- butyl benzoate
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- - Source and lot/batch No.of test material:
8684-90
- Storage of the test item: the samples were stored in a specific room, at room temperature, protected from humidity and light
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Currently, no acceptable non-animal alternative methodology is accepted by the relevant regulatory agencies. The rat was selected because this species has proven to be sensitive to chemicals; the rat is the preferred rodent species for prenatal developmental toxicity studies because of its small size, short gestation period, high fertility rate, large litter size and ease of maintenance. The Wistar Hannover rat was selected due to the large amount of background knowledge accumulated on this strain.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BIOAGRI Laboratorios
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 11 - 12 weeks old
- Weight at study initiation: Males 352.3±20.7 - 359.5±19.9 grams; Females 216.2± 8.6 - 220.4 ± 9.6 grams
- Fasting period before study: no data
- Housing: Each animal was housed individually, except during cohabitation. After acclimation one male was placed into each female cage for pairing. After pairing, females that presented vaginal smears with the presence of sperm were considered mated and housed individually. The rats were housed in polypropylene cages (41x34x19 cm) with wire mesh tops and bedding material (wood shavings). Clean cages were provided twice weekly for all animals. The cages with the test animals were arranged on the racks in such a way that uniform experimental conditions (ventilation and light) were ensured.
During gestation period all females were housed individually in the cages. Females without copulation date were housed in individual cages at the end of the mating period. Females showing no evidence of copulation were euthanized 24-26 days after the last day of mating period.
- Diet (e.g. ad libitum): ad libitum, Nuvilab CR-1 diet for rats supplied by Nuvital Nutrientes Ltda.
- Water (e.g. ad libitum): ad libitum, supplied by CAESB (Compania de Saneamento Ambiental do Distrito Federal) in water bottles
- Acclimation period: 5 days prior to dosing
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.0 - 24.4° C
- Humidity (%): 40.8 - 70.0%
- Air changes (per hr): 10-20 air changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- - PREPARATION OF DOSING SOLUTIONS:
- For each dosage group, the appropriate amount of JEFFSOL® AG 1700 was weighed into a precalibrated beaker. The vehicle (corn oil) was added in sufficient quantity to achieve the desired concentration. Each solution was homogenized and dispensed into individual containers properly identified. A sufficient quantity of the vehicle was similarly dispensed for administration to control animals.
- the prepared dolutions were stored at room temperature.
- Test solutions were prepared daily at the testing facility and were administered within 2 hours after preparation. The test solutions were stirred continuously during the administration to maintain homogeneity.
- VEHICLE
- Justification for use and choice of vehicle (if other than water):
- Amount of vehicle (if gavage): 1 ml/250g body weight. - Details on mating procedure:
- - M/F ratio per cage: 1 female: 1 male
- Length of cohabitation: until evidence of copulation is observed or 2 weeks had elapsed
- Proof of pregnancy: . Vaginal smears were collected daily during mating period and examined for the presence of sperm.
Day O of gestation was defined as the day a sperm was found in the vaginal smear. - Analytical verification of doses or concentrations:
- no
- Frequency of treatment:
- daily administration, on a 7 day per week basis
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Group 1, vehicle only
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Remarks:
- Group 2, the expected dose which causes no signs of toxicity
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- Group 3, the intermediate dose level
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- Group 4, the expected dose which causes signs of systemic toxicity, but not death or severe suffering
- No. of animals per sex per dose:
- 12 animals/sex/group
5 animals/sex/satllite group - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dosage levels (in mg/kg body weight/day) were selected in agreement with the Sponsor, based upon the results of a dose range-finding study (P.T. 3984.329.003.11).
- Rationale for animal assignment (if not random): randomized - Positive control:
- No
Examinations
- Parental animals: Observations and examinations:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
- All animals underwent a daily clinical observation for overt signs of ill health. These included, but were not limited to, changes in skin and fur, eye and mucous membranes, respiratory, circulatory, autonomic and central nervous system, motor activity and behavioral patterns.
BODY WEIGHT: Yes
- Time schedule for examinations: Males were weighed on the first day of dosing and weekly thereafter (including mating and post-mating periods). Females were weighed on first day of dosing and once a week during premating and mating periods, on days 0, 7, 14 and 20 of gestation, and during lactation on the same days as the weighing of litters (on days 0 and 4 postnatal).
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
Food consumption of females was determined on the same day of body weight determination during premating and lactation periods. During the gestation period, food consumption was determined on days 3, 6, 9, 12, 15, 18 and 20. After the mating period, food consumption of males was determined weekly. Food consumption was not determined during the mating period.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on the day of scheduled necropsy
- Anaesthetic used for blood collection: Yes, animals were anesthetized by CO2 prior to blood collection (cardiac puncture).
- Animals fasted: Yes , overnight
- How many animals: 5 parental animals/sex/group, randomly selected
- Parameters examined: Red Blood Cell Count (RBC), Hemoglobin (HB), Hematocrit (HCT), Platelets (PLT), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC), Total White Blood Cell Count (WBC), Differential Leukocyte Count, Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the day of scheduled necropsy.
- Animals fasted: Yes, overnight
- How many animals: 5 parental animals/sex/group, randomly selected
- Parameters examined: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Total Protein (TP), Albumin (ALB), Glucose (GLU), Total Cholesterol (CHOL), Urea Nitrogen (BUN), Creatinine (CREA), Sodium (Na), Potassium (K), Calcium (Ca), Globulin (GLOB), Albumin/Globulin Ratio (A/G)
FUNCTIONAL OBSERVATIONS: yes
Sensory reactivity to stimuli and motor activity assessment were performed in 5 animals/sex/group. For males these evaluations were performed at the end of the dosing period before scheduled necropsy, and for females, these evaluations were performed during the lactation period (day 3). The following parameters were assessed:
A - Autonomic Functions: lacrimation, salivation, palpebral closure, prominence of the eye, piloerection and respiration.
B - Reactivity and Sensitivity: sensor motor responses to approach tactile and tail flick. C - Excitability: reactions to handling and behavior in an open field.
D - Gait and Sensor Motor Coordination: degree of mobility and gait pattern in an open field.
E - Abnormal Clinical Signs: including convulsions, tremors, unusual behavior and deposits around the eyes, nose or mouth. - Oestrous cyclicity (parental animals):
- Not examined
- Sperm parameters (parental animals):
- Not examined
- Litter observations:
- Live pups were counted, sexed and weighed on days 0 and 4 postnatal.
The day when delivery is completed was designated day O of lactation (postnatal day 0). On day O of lactation the number of alive and dead pups/sex were recorded. Dams with offspring were euthanized on day 4 postnatal. All pups were euthanized at day 4 postnatal. - Postmortem examinations (parental animals):
- GROSS PATHOLOGY: Yes
At termination, all parental animals were examined macroscopically for any structural abnormalities or pathological changes. The animals were euthanized in a carbon dioxide chamber. The numbers of implantation sites and corpora lutea were recorded. Animals found dead were necropsied, discarded in biological garbage and incinerated.
ORGAN WEIGHTS:
- At scheduled necropsy, testes and epididymides of all males were weighed.
- Organ weights were obtained for the following organs from 5 animals/sex/group: liver; kidneys; adrenals; thymus; spleen; brain; heart.
HISTOPATHOLOGY: Yes
- For all animals necropsied, tissues were preserved in 10% neutral buffered formalin (except for the testes, which were preserved in Davidson's fixative)
- At scheduled necropsy, the following organs of all animals were preserved: testes, epididymides, ovaries, prostate, seminal vesicle and coagulating gland , bulbourethral gland ,organs showing alterations
- The following organs and tissues of 5 animals/sex/group were preserved: adrenals (right and left); bone marrow (femur); brain (cerebrum, cerebellum and pons); heart; intestine (duodenum, jejunum, ileum - including Peyer's patches, colon, rectum/anus); kidneys (right and left); liver (3 lobes); lungs; lymph nodes (mesenteric and submaxillary); peripheral nerve (sciatic); spinal cord (cervical, midthoracic and lumbar sections); spleen; stomach (glandular and non-glandular); trachea; thymus; thyroid; urinary bladder; uterus; all gross lesions.
- Full histopathology of the preserved organs and tissues listed above were performed in high dose and control animals. - Postmortem examinations (offspring):
- All pups were grosly examined for abnormalities of the oral, thoracic and abdominal cavities.
- Statistics:
- Quantitative variables such as body weights, food consumption and organs weights were analyzed by One Way Analysis of Variance (ANOVA), followed by Dunnett's test if significance is detected, or by the non-parametric test of Kruskal-Wallis, according to the results of tests for normality and homogeneity of variance. For qualitative or non-parametric data such as clinical findings, macroscopic and microscopic findings and fetal findings, comparison between means were carried out using Fisher's Exact Test or the Chi-Square Test.
The level of significance was set at 5%. - Reproductive indices:
- Mating index index (%): (number of female mated x 100/ number of females paired)
Fertility index (%): (number of pregnant animals/number of presumed pregnant animals) x 100
Preimplantation loss (%): (no. of corpora lutea - number of implantations/number of corpora lutea) x 100 - Offspring viability indices:
- Postimplantation loss (%): (number of implantations-number of live fetuses/ number of implantations) x 100
Gestation index (%): (number of female with live pups at birth x 100 /number of pregnant animals) x 100
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs were observed.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality occurred during the study.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No alteration on body weight in treated males was observed when compared to the control group. Lower body weight gain was observed in males exposed to 250 mg/kg/day between days 7 to 14 (-11.3%) and days 28 to 35 (-16%). Similar diminution on body weight gain was observed in males at 500 mg/kg/day between days 14 to 21 (-55.8%) and at 1000 mg/kg/day between days 7 to 14 and days 14 to 21 (-6.5% and -97.7%, respectively). In all cases, these changes were not considered to be test item related, because they were isolated, not statistically significant and did not affect overall body weight gain.
In treated satellite males, at the end of the first observation interval no alteration on body weight was observed, but some variations on body weight gain occurred, however, these variations did not affect overall body weight gain. In the recovery period, lower body weight gain occurred (- 29.7%), but was not statistically significant and did not affect the body weight. This finding was not considered to be test item related.
No alteration on body weight was observed in treated females compared to the control group. Differences on body weight gain were observed at several observation periods, affecting overall body weight gain in the gestation period (-15.7% low, -11.9% mid and -10.6% high dose) and lactation period (-60.9% low, -18.6% mid and -51.9% high dose). These differences were not dose related and not statistically significant, and therefore were not considered to be test item related.
In treated satellite females, at the end of the first observation period no alteration on body weight was observed, but some variations on body weight gain, statistically significant between days 0 to 21 were observed, but did not affect total body weight gain. In the recovery period, although the body weight gain was decreased (-57.5%), this change did not affect overall body weight, therefore this finding was considered incidental. - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Differences in food consumption were observed in treated males when compared to the control group.
Similar effects occurred in treated satellite males. Although these differences were sometimes statistically significant, they did not affect overall food consumption in either treated males or treated satellite males.
In treated females, differences in food consumption were observed, with statistical significance at some observation periods. In the lactation period, these differences were observed in high dose females, statistically significantly affecting overall food consumption (-24.46%) compared to the control group. This finding was not considered to be test item related since the body weight was not affected.
Statistically significant differences in food consumption were observed at several observation periods in treated satellite females, affecting total food consumption (-5%) in the first observation period and (-8.8%) in the recovery period compared to the control group. These findings were small and did not affect overall body weight, and, therefore are not considered to be test item related. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In treated males at 500 mg/kg/day, statistically significant higher lymphocytes counts were observed (+7.8%) but considered incidental because they occurred at the mid dose group. No other alterations on hematological and clotting parameters were observed in treated males.
Mean hemoglobin in treated satellite males was statistically significant lower (-6.7%) compared to the control group, but this finding was not considered to be test item related, because the difference was very small, and within Bioagri's historical range (14.1-17.9). No other hematological parameters were affected.
Statistically significant higher hematocrit (+6.6%) was observed in females exposed to 250 mg/kg/day, but it was an isolated finding at low dose, and therefore not considered to be test item related.
Statistically significant higher mean corpuscular hemoglobin concentration was noted in treated satellite females (+2.8%), but the difference was very small and considered incidental, as a normal biological variation.
In treated satellite males, white blood cell counts (-30.1%) and total lymphocyte counts (-34%) were lower than control group. Total lymphocyte count is within Bioagri's historical range and total white blood cells count is slightly outside (-3.9%). Considering this difference very small in magnitude and no other white cells were affected, this finding was not considered to be test item related. No other changes in white blood cells were observed.
Changes in clotting parameters were observed in both prothrombin time in females at 1000 mg/kg/day (+11.8%) and in treated satellite females (+7.2%), statistically significant in both cases. These
values were small and are within Bioagri's baseline (13.5-23.1) and are not considered to be test item related.
For more detailed information, see section 'Any other information on results' - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In treated males, statistically significantly lower creatinine (-20%) at 500 mg/kg/day and albumin (-7.7% low and -15.4% mid dose) were observed compared to the control group, but not considered to be dose related.
No alteration in the clinical chemistry parameters were noted in treated female groups. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No alteration in the Functional Observation Battery was found in male or female treated groups compared to the control.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Slight reduction of germ cells (bilateral) was the most common lesion noted. This finding was observed in three males exposed to 1000 mg/kg/day. This change should not be considered to be test item related, since this focal isolated reduction of germ cells unilateral in epididymis was also observed in two treated satellite males and two control satellites.
Other microscopic lesions were observed in two animals; one male, at 1000 mg/kg/day presented erosion in the stomach mucosa, and in one female presented focal chronic proliferative nephropathy in the left kidney. These lesions were considered normal background findings and were not considered to be test item related.
For more detailed information, see section 'Any other information on results' - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Similar gestation index were observed when treated groups were compared to the controls and no differences were observed. In dams exposed to the high dose, the number of total pups and the number of live pups at day 0 were lower compared to the control group. These findings, while decreased compared to controls, were not statistically significant and are not likely to be test item related.
For further detailed information, see section 'Any other information on results'
Details on results (P0)
In this study, the alterations occurred at high dose levels in male and female. These changes were observed on testes (slight reduction of germ cells) and reproductive parameters. Slight reduction of germ cells was observed in three males exposed to the highest dose level. This result was not considered test item related because this lesion appeared in equal proportions in both control and high dose satellites and the frequency of this lesion was not statistically significant. Despite that these males produced offspring from their respective females.
Effect levels (P0)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- parental
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproductive
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity (P0)
- Key result
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No specific findings in all animals.
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- While the absolute number of dead pups in the high dose group was statistically significantly increased when compared to controls on day 0, the mean number of live and dead pups per litter was not significantly increased when compared to controls on day 4. No differences were observed when delivery day 1 was compared to day 4 postnatal.
For further information, see section 'Any other information on results' - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No difference in pup body weight was observed between the treated and control groups at day 0. The body weight of pups at day 4 postnatal were lower compared to the control group. This finding, while decreased compared to controls, was not statistically significant and is not likely to be test item related.
For further information, see section 'Any other information on results' - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No macroscopic finding was observed in treated or control groups.
- Histopathological findings:
- no effects observed
- Other effects:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Details on results (F1)
Effect levels (F1)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity (F1)
- Key result
- Critical effects observed:
- no
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- no
Any other information on results incl. tables
Hematology: data is presented as mean+/-SD (No. animals)
Parameter |
unit |
group |
0 mg/kg/day (Control) |
250 mg/kg/day |
500 mg/kg/day |
1000 mg/kg/day |
WBC |
/mm3 |
Males |
5360+/-2304 (5) |
6640+/-1569 (5) |
5500+/-1158 (5) |
5040+/-2556 (5) |
WBC |
/mm3 |
Satellite males |
5180+/-832 (5) |
|
|
3620+/-1246* (5) |
WBC |
/mm3 |
Females |
3260+/-1316 (5) |
3040+/-1234 (5) |
3500+/-1030 (5) |
4680+/-2989 (5) |
WBC |
/mm3 |
Satellite females |
3180+/-853 (5) |
|
|
3580+/-1743 (5) |
Lymphocytes |
/mm3 |
Males |
4333+/-2148 (5) |
5027+/-1550 (5) |
4744+/-981 (5) |
3917+/-1886 (5) |
Lymphocytes |
WBC% |
Males |
78.6+/-10.1 (5) |
76.0+/-13.2 (5) |
86.4+/-4.2* (5) |
79.0+/-6.5 (5) |
Lymphocytes |
/mm3 |
Satellite males |
4249+/-705 (5) |
|
|
2801+/-876* (5) |
Lymphocytes |
WBC% |
Satellite males |
82.0+/-2.0 (5) |
|
|
78.2+/-6.4 (5) (5) |
Lymphocytes |
/mm3 |
Females |
2546+/-1140 (5) |
2420+/-1028 (5) |
2611+/-890 (5) |
3867+/-2563 (5) |
Lymphocytes |
WBC% |
Females |
77.2+/-4.6 (5) |
79.2+/-5.6 (5) |
74.0+/-9.0 (5) |
81.4+/-3.4 (5) |
Lymphocytes |
/mm3 |
Satellite females |
3455+/-741 (5) |
|
|
2735+/-1348 (5) |
Lymphocytes |
WBC% |
Satellite females |
76.8+/-7.4 (5) |
|
|
76.6+/-5.0 (5) |
PT |
sec |
Males |
14.4+/-1.2 (5) |
14.1 +/-1.0 (5) |
14.8+/-0.8 (5) |
14.2+/-1.3 (5) |
PT |
sec |
Satellite males |
19.9+/-0.6 (5) |
|
|
19.5+/-0.9 (5) |
PT |
sec |
Females |
13.6+/-0.7 (5) |
14.6+/-0.8 (5) |
13.6+/-1.0 (5) |
15.2+/-0.8* (4) |
PT |
sec |
Satellite females |
19.5+/-0.7 (5) |
|
|
20.9+/-0.8* (4) |
hemoglobin |
g/dL |
Males |
15.66+/-3.11 (5) |
16.36+/-0.61 (5) |
15.96+/-1.00 (5) |
16.32+/-0.76 (5) |
hemoglobin |
g/dL |
Satellite males |
16.18+/-0.44 (5) |
|
|
15.10+/-0.75* (5) |
hemoglobin |
g/dL |
Females |
14.74+/-0.46 (5) |
15.36+/-0.51 (5) |
15.30+/-0.64 (5) |
13.16+/- 3.97 (5) |
hemoglobin |
g/dL |
Satellite females |
15.18+/-0.87 (5) |
|
|
15.38+/-0.41 (5) |
Hematocrit |
% |
Males |
48.64+/-10.08 (5) |
50.32+/-2.09 (5) |
49.52+/-3.38 (5) |
50.56+/-2.71 (5) |
Hematocrit |
% |
Satellite males |
47.66+/-0.74 (5) |
|
|
45.06+/-2.81 (5) |
Hematocrit |
% |
Females |
45.04+/-1.60 (5) |
48.02+/-1.35* (5) |
47.46+/-3.64 (5) |
41.28+/-12.65 (5) |
Hematocrit |
% |
Satellite females |
45.54+/-2.49 (5) |
|
|
44.92+/-1.47 |
MCHC |
g/dL |
Males |
32.22+/-0.48 (5) |
32.48+/-0.26 (5) |
32.24+/-0.34 (5) |
32.28 +/- 0.72 (5) |
MCHC |
g/dL |
Satellite males |
33.96+/-0.59 (5) |
|
|
33.58+/-0.74 (5) |
MCHC |
g/dL |
Females |
32.74+/-0.99 (5) |
31.94+/-0.76 (5) |
32.34+/-1.22 (5) |
31.98+/-0.45 (5) |
MCHC |
g/dL |
Satellite females |
33.34+/-0.56 (5) |
|
|
34.26+/-0.43* (5) |
* statistically significant p<0.05 difference between the means of the group treated and control group
Organ weight: data is presented as mean+/-SD (N° of animals)
Organ |
|
group |
0 mg/kg/d (control) |
250 mg/kg/day |
500 mg/kg/day |
1000 mg/kg/day |
Right testis |
Absolute weight |
Males |
2.027+/-0.153 (12) |
2.038+/-0.180 (12) |
1.978+/-0.158 (12) |
1.879+/-0.186 (12) |
Right testis |
Relative to body weight |
Males |
0.527+/-0.043 (12) |
0.509+/-0.048 (12) |
0.492+/-0.048 (12) |
0.476+/-0.044* (12) |
Right testis |
Relative to brain weight |
Males |
99.36+/-7.73 |
96.44+/-8.55 |
101.96+/-6.94 |
95.13+/-7.23 |
Left testis |
Absolute weight |
Males |
2.061+/-0.209 (12) |
2.048+/-0.198 (12) |
2.030+/-0.162 (12) |
1.937+/-0.194 (12) |
Left testis |
Relative to body weight |
Males |
0.535+/-0.047 (12) |
0.511+/-0.054 (12) |
0.506+/-0.053 (12) |
0.491+/-0.051 (12) |
Left testis |
Relative to brain weight |
Males |
98.71+/-9.58 (12) |
94.97+/-7.02 (12) |
103.45+/-8.34 (12) |
96.97+/-7.94 (12) |
Right testis |
Absolute weight |
Satellite males |
2.120+/-0.188 (5) |
|
|
1.866+/-0.212 (5) |
Right testis |
Relative to body weight |
Satellite males |
0.505+/-0.058 (5) |
|
|
0.450+/-0.034 (5) |
Right testis |
Relative to brain weight |
Satellite males |
102.18+/-11.32 (5) |
|
|
95.19+/-10.67 (5) |
Left testis |
Absolute weight |
Satellite males |
2.033+/-0.201 (5) |
|
|
1.990+/-0.185 (5) |
Left testis |
Relative to body weight |
Satellite males |
0.483+/-0.052 (5) |
|
|
0.481+/-0.040 (5) |
Left testis |
Relative to brain weight |
Satellite males |
97.99+/-11.82 (5) |
|
|
101.45+/-8.77 (5) |
* statistically significant (p<0.05)
Histopathology: individual data (presented as x out of y animals)
Organ |
observation |
Group |
0 mg/kg/day |
250 mg/kg/day |
500 mg/kg/day |
1000 mg/kg/day |
Testis (bilateral) |
Slight reduction of germ cells |
Males |
0/12 |
- |
- |
3/12 |
Epididymis (right) |
Focal isolated reduction of germ cells |
Satellite males |
2/5 |
- |
- |
2/5 |
Reproduction data of dams on day 0
Test group |
Animal/litter number |
|
Total pups |
N° of live pups |
N° of dead pups |
0 mg/kg/day (control) |
13 |
Not pregnant |
- |
- |
- |
|
14 |
|
11 |
11 |
0 |
|
15 |
|
11 |
11 |
0 |
|
16 |
No viable pups |
0 |
0 |
0 |
|
17 |
|
11 |
11 |
0 |
|
18 |
|
6 |
6 |
0 |
|
19 |
Not pregnant |
- |
- |
- |
|
20 |
Not pregnant |
- |
- |
- |
|
21 |
|
8 |
8 |
0 |
|
22 |
|
13 |
13 |
0 |
|
23 |
No viable pups |
0 |
0 |
0 |
|
24 |
|
11 |
11 |
0 |
|
Total |
|
71 |
71 |
0 |
|
Mean+/-SD (N° animals) |
|
7.9+/-4.9 (9) |
7.9+/-4.9 (9) |
0+/-0 (9) |
250 mg/kg/day |
47 |
Not pregnant |
- |
- |
- |
|
48 |
|
3 |
3 |
0 |
|
49 |
|
10 |
10 |
0 |
|
50 |
|
12 |
12 |
0 |
|
51 |
|
10 |
10 |
0 |
|
52 |
|
4 |
4 |
0 |
|
53 |
|
6 |
6 |
0 |
|
54 |
Not pregnant |
- |
- |
- |
|
55 |
Not pregnant |
- |
- |
- |
|
56 |
|
7 |
7 |
0 |
|
57 |
|
8 |
8 |
0 |
|
58 |
|
10 |
10 |
0 |
|
Total |
|
70 |
70 |
0 |
|
Mean+/-SD (N° animals) |
|
7.8+/-3.0 (9) |
7.8+/-3.0 (9) |
0+/-0 (9) |
500 mg/kg/day |
71 |
|
5 |
4 |
1 |
|
72 |
Not pregnant |
- |
- |
- |
|
73 |
|
1 |
1 |
0 |
|
74 |
|
7 |
7 |
0 |
|
75 |
|
9 |
9 |
0 |
|
76 |
|
2 |
2 |
0 |
|
77 |
|
11 |
11 |
0 |
|
78 |
|
12 |
11 |
1 |
|
79 |
|
11 |
11 |
0 |
|
80 |
|
9 |
9 |
0 |
|
81 |
|
10 |
10 |
0 |
|
82 |
Not pregnant |
- |
- |
- |
|
Total |
|
77 |
75 |
2 |
|
Mean+/-SD (N° animals) |
|
7.7+/-3.9 (10) |
7.5+/-3.8 (10) |
0.2+/-0.4 (10) |
1000 mg/kg/day |
95 |
No viable pups |
0 |
0 |
0 |
|
96 |
|
7 |
5 |
2 |
|
97 |
|
7 |
0 |
7 |
|
98 |
|
3 |
0 |
3 |
|
99 |
|
12 |
12 |
0 |
|
100 |
|
10 |
10 |
0 |
|
101 |
|
10 |
10 |
0 |
|
102 |
|
4 |
4 |
0 |
|
103 |
|
5 |
5 |
0 |
|
104 |
|
3 |
3 |
0 |
|
105 |
Not pregnant |
- |
- |
- |
|
106 |
Not pregnant |
- |
- |
- |
|
Total |
|
61 |
49 |
12 |
|
Mean+/-SD (N° animals) |
|
6.1+/-3.8 (10) |
4.9+/-4.5 (10) |
1.2+/-2.3 (10) |
Individual body weights (g) of pups
Test group |
Litter number |
Day 0 postnatal mean pup weight |
Day 4 postnatal mean pup weight |
0 mg/kg/day (control) |
14 |
6.4 |
9.9 |
|
15 |
6.6 |
11.2 |
|
17 |
6.7 |
10.6 |
|
18 |
5.3 |
8.1 |
|
21 |
6.7 |
13.0 |
|
22 |
6.4 |
9.7 |
|
24 |
5.7 |
9.3 |
|
Mean+/-SD (N° of animals) |
6.3+/-0.5 (7) |
10.3+/-1.6 (7) |
250 mg/kg/day |
48 |
7.6 |
12.3 |
|
49 |
6.7 |
9.7 |
|
50 |
5.7 |
8.8 |
|
51 |
6.0 |
9.4 |
|
52 |
7.3 |
12.2 |
|
53 |
7.0 |
11.4 |
|
56 |
6.5 |
9.1 |
|
57 |
6.1 |
9.1 |
|
58 |
6.2 |
10.1 |
|
Mean+/-SD (N° of animals) |
8.6+/-0.6 (9) |
10.2+/-1.4 (9) |
500 mg/kg/day |
71 |
8.5 |
10.2 |
|
73 |
4.6 |
- |
|
74 |
6.5 |
11.6 |
|
75 |
6.7 |
11.8 |
|
76 |
7.1 |
9.1 |
|
77 |
5.6 |
10.1 |
|
78 |
5.9 |
10.7 |
|
79 |
7.3 |
12.7 |
|
80 |
6.4 |
10.3 |
|
81 |
6.1 |
10.5 |
|
Mean+/-SD (N° of animals) |
6.3+/-0.8 (10) |
10.8+/-1.1 (9) |
1000 mg/kg/day |
96 |
5.4 |
3.6 |
|
99 |
5.9 |
8.0 |
|
100 |
6.3 |
11.2 |
|
101 |
5.3 |
7.8 |
|
102 |
7.4 |
13.0 |
|
103 |
6.6 |
8.7 |
|
104 |
6.9 |
11.8 |
|
Mean+/-SD (N° of animals) |
6.3+/-0.8 (7) |
9.2+/-3.2 (7) |
Applicant's summary and conclusion
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) of the test item in Wistar rats was 1000 mg/kg/day for males and females and 1000 mg/kg/day for embryo-fetal toxicity. The substance is not to be classified as reproductive toxicant.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
